Skip to main content
Top
Published in: Pediatric Drugs 3/2024

02-04-2024 | Antibiotic | Review Article

Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention

Authors: Annette Gawron Roberts, Noelle Younge, Rachel Gottron Greenberg

Published in: Pediatric Drugs | Issue 3/2024

Login to get access

Abstract

Necrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, maternal and environmental factors, and intestinal ischemia) and reports treatment modalities surrounding NEC, including pain medications and common antibiotic combinations, the rationale for these combinations, and recent antibiotic stewardship approaches surrounding NEC treatment. This review also highlights the effect of early antibiotic exposure, infections, proton pump inhibitors (PPIs), and H2 receptor antagonists on the microbiota and how these risk factors can increase the chances of NEC. Finally, modern prevention strategies including the use of human breast milk and standardized feeding regimens are discussed, as well as promising new preventative and treatment options for NEC including probiotics and stem cell therapy.
Literature
69.
go back to reference Moscovici O, Chany C, Lebon P, Rousset S, Laporte J. Association of coronavirus infection with hemorrhagic entercolitis in newborn infants. C R Seances Acad Sci D. 1980;290(13):869–72.PubMed Moscovici O, Chany C, Lebon P, Rousset S, Laporte J. Association of coronavirus infection with hemorrhagic entercolitis in newborn infants. C R Seances Acad Sci D. 1980;290(13):869–72.PubMed
85.
155.
go back to reference FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. Warning Letters Issued to Two Companies for Illegally Selling Probiotic Products to Treat Diseases in Preterm Infants. FDA News Release: US Food & Drug Administration; 2023. FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. Warning Letters Issued to Two Companies for Illegally Selling Probiotic Products to Treat Diseases in Preterm Infants. FDA News Release: US Food & Drug Administration; 2023.
163.
go back to reference Chowdhury T, Ali MM, Hossain MM, et al. Efficacy of probiotics versus placebo in the prevention of necrotizing enterocolitis in preterm very low birth weight infants: a double-blind randomized controlled trial. J Coll Physicians Surg Pak. 2016;26(9):770–4.PubMed Chowdhury T, Ali MM, Hossain MM, et al. Efficacy of probiotics versus placebo in the prevention of necrotizing enterocolitis in preterm very low birth weight infants: a double-blind randomized controlled trial. J Coll Physicians Surg Pak. 2016;26(9):770–4.PubMed
Metadata
Title
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Authors
Annette Gawron Roberts
Noelle Younge
Rachel Gottron Greenberg
Publication date
02-04-2024
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 3/2024
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-024-00626-w

Other articles of this Issue 3/2024

Pediatric Drugs 3/2024 Go to the issue